The purpose of this study is to create and test a patient decision aid that facilitates the shared decision-making process when patients with psoriasis and/or psoriatic arthritis are starting or switching to a new therapy.

Prior to the interventional study, we will develop a decision aid using design thinking. In this interventional study, we will implement and test a patient-centered decision aid for therapy selection among patients with psoriasis and/or psoriatic arthritis who are starting or switching to a new medication.

Inclusion Criteria:

1. Age 18 years or older

2. Diagnosis of psoriasis (as confirmed by dermatologist) or psoriatic arthritis (as confirmed by rheumatologist)

3. Treated at Penn

   In addition to the above, for the observation and implementation phases of the study:

4. Initiation of a new psoriasis or psoriatic arthritis treatment

   • Biosimilars that have been approved by the FDA and available on the US market will similarly be eligible for participation
   • Patients may be taking other traditional DMARDs.
   • A washout period is not required.

Exclusion Criteria:

1. Unable to give informed consent

2. Youth, under the age of 18 years

3. Patients without psoriasis or psoriatic arthritis

4. Not being treated at a Penn clinic

   In addition to the above, for the observation and implementation phases of the study:

5. Not starting or switching to a new medication

Participant data will be used to create the decision aids which will then be made available to patients, researchers, and medical centers. Physicians and researchers may request de-identified data from the PI and research plans will be reviewed on a case by case basis.

Participants will have a choice of decision aids (web or paper) and will not be blinded. The study team will be aware of each prototype and decision aid that participants use.